---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-023834"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:16:08.887643+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LIXTE collaborates with Roche and NKI on trial combining LB-100 with atezolizumab in MSI Low colon cancer

## Summary
- Trial (NCT06012734) will test LB-100 plus Roche's PD-L1 inhibitor atezolizumab in immunotherapy-unresponsive MSI Low metastatic colon cancer.
- LIXTE provides LB-100; Roche provides atezolizumab via imCORE Network; NKI is principal investigator.
- About 85% of colon cancers are MSI Low; LB-100 may sensitize these tumors to immunotherapy, expanding treatment options.
- This is second recent pharma-backed trial combining LB-100 with immunotherapy; GSK is funding a separate trial in clear cell ovarian cancer.
- New pre-clinical data in EMBO Reports showed LB-100 can turn immunologically 'cold' tumors 'hot'.

## SEC filing metadata
- accession: 0001493152-24-023834
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224023834/0001493152-24-023834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224023834/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-023834
- JSON: https://secwatch.observer/filing/0001493152-24-023834.json
- Plain text: https://secwatch.observer/filing/0001493152-24-023834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.